May 14th 2024
Dynavax is currently reviewing FDA feedback and strategizing a meeting to discuss their HEPLISAV-B four-dose regimen for hemodialysis patients, determining the path forward toward approval.
Top 5 Infectious Disease News Stories Week of April 20- April 26
April 26th 2024Public health alert over ground beef, FDA approves antibiotics for female adults with uncomplicated UTI, The NYC Department of Health and Mental Hygiene reports a record amount of Leptospirosis cases, and more this week from Contagion.
Read More
Top 5 Infectious Disease News Stories: April 13-April 19
April 19th 2024Study highlighting the first documented case of C auris moving from adult to pediatric unit in Maryland, COVID-19 physical health problems lingering 1 year after their hospital stay, 5-in-1 meningococcal vaccine given FDA PDUFA, and more this week from Contagion.
Read More
Top 5 Infectious Disease Stories Week of March 9
March 15th 2024A vaccine targeting chronic HBV has entered its first human trial; Saskia Popescu, PhD, on the importance of pandemic preparedness and global health security; a successful phase 2 trial for a C diff treatment leads to the next phase; and more stories this week from Contagion.
Read More
This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.
Read More
Let's Call March, Hepatitis Education Month
March 2nd 2024In thinking about the international and national public health campaigns to eliminate hepatitis, is general awareness of the disease enough to motivate treatment-hesitant hepatitis patients to accept clinical care, or does there need to be a greater commitment beyond that?
Read More
Top 5 Infectious Disease Stories: Week of February 25
March 1st 2024This week, why measles and vibrio vulnificus infections are seeing outbreaks and increases in incidence rates; a medical association recommends fecal microbiota-based therapies for recurrent or severe C difficile; and an antiviral reduced a median time-to-symptom resolution.
Read More